Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
2.480
+0.010 (0.40%)
At close: Dec 5, 2025, 4:00 PM EST
2.570
+0.090 (3.63%)
After-hours: Dec 5, 2025, 6:51 PM EST
Chemomab Therapeutics Stock Forecast
CMMB's stock price has decreased by -62.87% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Chemomab Therapeutics stock ranges from a low of $25 to a high of $28. The average analyst price target of $26.5 forecasts a 968.55% increase in the stock price over the next year.
Price Target: $26.50 (+968.55%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 27, 2025.
Analyst Ratings
The average analyst rating for Chemomab Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $25 | Buy | Maintains | $10 → $25 | +908.06% | Aug 27, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $44 → $40 | Buy | Maintains | $44 → $40 | +1,512.90% | May 16, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $16 → $28 | Strong Buy | Maintains | $16 → $28 | +1,029.03% | Feb 20, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $52 → $44 | Buy | Reiterates | $52 → $44 | +1,674.19% | Nov 15, 2024 |
| Maxim Group | Maxim Group | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +545.16% | May 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.16
from -3.11
EPS Next Year
-0.16
from -0.16
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.17 | -0.17 | ||||
| Avg | -0.16 | -0.16 | ||||
| Low | -0.16 | -0.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.